COCOON Trial: Prophylactic Dermatologic Protocol Halves Skin Toxicities in EGFR-Mutant NSCLC Patients on Amivantamab-Lazertinib
Key Insights
The phase II COCOON trial demonstrated that a structured prophylactic dermatologic regimen reduced grade ≥2 skin adverse events from 76.5% to 38.6% in patients receiving first-line amivantamab plus lazertinib for EGFR (search)-mutant NSCLC.
The prophylaxis protocol included oral doxycycline or minocycline, ceramide-based moisturization, chlorhexidine nail care, and topical clindamycin, representing low-cost, straightforward interventions.
Reductions in grade ≥3 events and treatment discontinuations were also observed, underscoring the value of integrating proactive supportive care into first-line treatment planning.
A structured dermatologic prophylaxis regimen has demonstrated the ability to dramatically reduce skin toxicities in patients receiving first-line amivantamab plus lazertinib for EGFR-mutant non-small cell lung cancer (search) (NSCLC), according to interim findings from the phase II COCOON trial published in Oncoscience.
The commentary, led by first and corresponding author Bishal Tiwari from Nassau University Medical Center and Asmita Koirala from Western Regional Hospital in Nepal, summarizes early results showing that the incidence of grade ≥2 dermatologic adverse events fell from 76.5% with standard reactive care to 38.6% with the prophylactic protocol.
A Multimodal Prevention Strategy
The COCOON regimen employed a combination of readily available interventions: oral doxycycline or minocycline, ceramide-based moisturization, chlorhexidine nail care, and topical clindamycin. These straightforward, low-cost measures were implemented proactively rather than waiting for toxicities to emerge, representing a paradigm shift from the reactive management approach that has historically accompanied EGFR (search)-targeted therapies.
The commentary also reports reductions in grade ≥3 events and treatment discontinuations, findings that carry significant implications for maintaining dose intensity and treatment adherence in this patient population.
Clinical Significance and Future Directions
"The COCOON results emphasize the clinical value of anticipating EGFR (search) inhibitor-related toxicities through multidisciplinary supportive care," the authors state in their published perspective.
The authors conclude that these interim results reinforce the need to integrate dermatologic prevention into first-line treatment planning for EGFR (search)-mutant NSCLC. They note that such interventions can improve tolerability and maintain dose intensity, and they anticipate that future clinical practice updates will likely incorporate this kind of proactive supportive care approach more broadly.
The research perspective was published in Volume 13 of Oncoscience on March 11, 2026, and provides an early look at how structured supportive care protocols may reshape the standard of care for patients initiating amivantamab-based combination therapy in the first-line setting.